Stem Cell Transplantation in Liver Diseases

Essay

Submitted for partial fulfillment of Master Degree in Tropical Medicine

Presented By

El-Sheshtawy Sayed Ahmed El-Sheshtawy M.B.B.Ch.

Supervisors

Prof. Dr. Mohamed Fawzy Montasser

Ex Dean Faculty of Medicine
Ain Shams University
Professor of Tropical Medicine
Faculty of Medicine
Ain Shams University

Prof. Dr. Amany Ahmed Ibrahim

Professor of Tropical Medicine Faculty of Medicine Ain Shams University

Prof. Dr. Essam Abd El-Wahed Hassan

Professor of Internal Medicine and Hematology
Faculty of Medicine
Ain Shams University

Faculty of Medicine Ain Shams University 2010

زراعة الخلايا الجذعية في أمراض الكبد

مقالة مقدمة من الششتاوى سيد أحمد الششتاوى بكالوريوس الطب والجراحة توطئة للحصول على درجة الماجستير في طب المناطق الحارة

تحت إشراف الدكتور/ محمد فوزى منتصر عميد كلية الطب جامعة عين شمس السابق أستاذ طب المناطق الحارة كلية الطب - جامعة عين شمس

الأستاذ الدكتور/ أمانى أحمد إبراهيم أستاذ طب المناطق الحارة علية الطب – جامعة عين شمس

الأستاذ الدكتور/ عصام عبد الواحد حسن أستاذ الباطنة وأمراض الدم علية الطب - جامعة عين شمس

كلية الطب جامعة عين شمس 2010

Acknowledgement



Thanks first to ALLAH, as we owe to him for his great care, support and guidance in every step in our life.

It's a great pleasure to acknowledge my deepest gratitude to **Prof. Dr. Mohamed Fawzy Montasser**, Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University, for his help, and kind supervision. I had the honor to work under his supervision. I appreciate his generous guidance, keen interest and precious time he offered me throughout this study.

I have to express my great pleasure to **Prof. Dr. Amany Ahmed Ibrahim**, Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University, for her continuous support, valuable remarks, meticulous supervision and for offering me much of her time and effort throughout this study. Her scientific advices were kindly given to me and are beyond acknowledgement.

I wish to express my deepest gratitude and appreciation to **Prof. Dr. Essam Abd El-Wahed Hassan,** Professor of internal Medicine and Hematology, Faculty of Medicine, Ain Shams University, for his continuous help, advice and his great effort in reading and correction of this work.

El-Sheshtawy Sayed Ahmed

List of Contents

Subject	Page
List of Abbreviations	I
List of Tables	IV
List of Figures	V
Introduction	1
Aim of the Essay	3
Chapter (1): Stem Cell	4
Stem cell definition	4
Properties of stem cells	4
Sources of stem cells	7
Stem cell plasticity	11
Stem cell and cancer	13
Types of stem cells	21
Stem cells markers	29
Ethics of stem cell research	33
Chapter (2): Application Of stem cell	36
Chapter (3): Liver anatomy, physiology and cirrhosis	60
Chapter (4): Stem cell therapy in liver diseases	89
Chapter (5): Complications of stem cell therapy	117
Summary	145
Conclusion and recommendation	147
References	148
Arabic Summary	25

List of Abbreviations

2-AAF : 2-acetylaminofluorene

AA : Allylalcohol

AAT : Alpha 1- antitrypsin deficiency

ABMI : Autologous bone marrow cell infusion

AECs: Amniotic epithelial cells

AFP : Alpha-fetoprotien

AGPR : Asialoglycoprotein receptor
ALD : Alcoholic liver disease

ALL : Acute lymphoblastic leukemia

allo-HCT : Allogeneic hematopoietic cell transplantation

ALS : Amyotrophic lateral sclerosis
ALT : Alanine aminotranferease
AML : Acute myeloid leukemia
APC : Activated protein C

APS: Anti phospholipid syndrome

ASCs: Adult Stem Cells

AST : Aspartate aminotransferase

ATG : Anti-thymocyte globulin

AVN : Avascular necrosis of bone

BAL : Bio-artificial liver : Bronchoalveolar lavage

Bc1-2 : Prototype for a family of mammalian genes and the proteins

they produce multidrug resistant gene MDRI

BMC : Bone marrow-derived cells

BMD : Bone marrow cells
: Bone mineral density

BMMSCs: Bone marrow mesenchymal stem cells

CB : Cord blood

CC14 : Carbon tetrachloride CD : Crohn's disease

CIMF
: Chronic idiopathic myelofibrosis
CLL
: Chronic lymphocytic leukemia
CML
: Chronic myeloid leukemia
CR1
: First clinical remission
CR2
: Second clinical remission

CSA : Cyclosporine

DDPIV+ : Diffuse alveolar haemorrhage : Dipeptidyl peptidase IV-positive

DFS: Disease free survival

DMARDs: Disease-modifying antirheumatic drugs

EBMT: European Group for Blood and Marrow Transplantation

ECM : Extracellular matrix : Embryonic stem cells

EULAR : European League against Rheumatism

F344 : Nagase analbuminemic rat FAH : Fumarylacetoacetate hydrolase

FBS: Fetal bovine serum

FISH : Fluorescence in situ hybridization

FL : Follicular lymphoma

FLRV: Future liver remnant volume

FSCs: Fetal stem cells

GFP : Green fluorescence proteinGFR : Glomerular filtration rate

GGT : Gamma-glutamile transpeptidase

GVHD : Graft-versus-host disease

HD : Hodgkin's disease

HGF : Hepatocyte growth factor
HHV-6 : Human herpes virus-6
HLA : Human leukocyte antigen
HSCs : Hematopietic stem cells

HSCT: Hematopietic stem cell transplantation

ICMs: Inner cell masses

IHBC : Intermediate hepatobiliary cells

: Interleukin-11

ISEMFs: Intestinal subepithelial myofibroblasts

LCT: Liver cell transplantation

LVEF : Left ventricular ejection fraction

MACSMagnetic cell sortingMyelodysplastic syndromes

MELD : Model of End-Stage Liver Disease
 MHC : Major histocompatibility complex
 MIBE : Measles inclusion body encephalitis

MMP-9 : Matrix metalloproteinase 9

MNCs : Mononuclear cells
MOH : Ministry of Health

MPB : Mobilized peripheral bloodMRI : Magnetic resonance imaging

MS: Multiple sclerosis

MSCs : Mesenchymal stem cells
MUD : Matched unrelated donors
NARS : Nagase analbuminemic rats
NASH : Non-alcoholic steatohepatitis

NHL: Non-Hodgkin lymphoma

OLT : Orthotopic liver transplantation

P450 . Phenobarbital-inducible cytochrome-P450

PCNA : Proliferating cell nuclear antigen

PDSCs : Placenta-derived stem cells
PVE : Portal vein embolization

RA : Rheumatoidarthritis

REPAIR- : Reinfusion of Enriched progenitor cells and Infarct

AMI Remodeling in A cute Myocardial Infarction

RSV : Respiratory syncytial virus

RT- PCR : Reverse Transcription-Polymerase Chain Reaction

Sca-1 : Stem cell antigen-1 : Stem cell factor

SCS : Stem cells

SCT : Stem cell transplar

SCT : Stem cell transplantationSDF-1 : Stromal cell-derived factor-1

SDF-1 : Stromal cell-derived factor-1 alpha alpha

SEC: Sinusoidal endothelial cells

SS : Systemic sclerosis STZ : Streptozotocin

TBI : Total body irradiation
TPO : Thrombopoietin

TRM : Transplant-related mortality

UC : Ulcerative colitis

UCB
Umbilical cord blood
Veno-occlusive disease
α-MEM
α minimal essential medium

List of Tables

Table		Comment	Page
Table	(1)	: Markers Used to Identify Stem Cells	32
Table	(2)	: Mortality in Egypt due to liver disease, 2001-	
		2006	83
Table	(3)	: Etiology of Fever in Patients with Persistent	
		Febrile Neutropenia despite Broad-Spectrum	
		Antibacterial antibiotics	119

List of Figures

Figure		Comment	Page
Fig.	(1)	: Pluripotent, embryonic stem cells originate as inner mass cells within a blastocyst	5
Fig.	(2)	: Identifying Cell Surface Markers Using Fluorescent Tags	30
Fig.	(3)	: Microscopic Image of Fluorescent-Labeled SC	31
Fig.	(4)	: Anatomy of the liver	60
Fig.	(5)	: Functional anatomy of the liver	62
Fig.	(6)	: Diagram of an acinus	66
Fig.	(7)	: Prevalence of anti-HCV in persons aged 10-50 years	79
Fig.	(8)	: Prevalence of anti-HCV in Cairo and the Nile Delta	
Fig.	(9)	: Hepatic cell types into which the bone marrow stem cells (BMSCs) may transform. SEC	80
Fig.	(10)	: Potential delivery approaches of bone marrow stem cells for liver diseases	92
			103

Introduction

Transplantation is an accepted treatment today for many people suffering from organ failure. More and more patients are referred for transplant surgery, and the waiting lists are growing longer because not enough organs and tissues are donated for transplantation. This has led to several potentially viable alternatives being considered, including bioartificial support devices, the transplantation of mature cells or stem/progenitor cells and the potential transplantation of xenogenic organs and cells (*Burra et al., 2004*).

Orthotopic liver transplantation (OLT) is the gold standard treatment for end-stage liver failure and for numerous liver based inborn errors of metabolism. However, organ shortage remains a major limiting factor and alternative solutions are being examined in the liver therapy field. Liver cell transplantation (LCT) is emerging with heartening success, but is still limited by cell viability, modest engraftment and limited tissue availability (Stephenne et al., 2006). Increasing interest is carried to stem cells regarding the recent demonstration of their plasticity (Verfaillie et al., 2002).

A stem cell is an undifferentiated cell capable of renewing itself throughout its life and of generating one or more types of differentiated cells. While embryonic stem cells (ESCs) are the only ones to be totipotential, adult tissues with high cellular turnover (e.g. skin, gut mucosa and bone marrow) retain a population of stem cells with restricted differentiation potential that constantly supply the tissue with new cells (*Heidelbaugh and Bruderly*, 2006).

The two broad types of mammalian stem cells are: embryonic stem cells that are found in blastocysts, and adult stem cells that are found in adult tissues. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing specialized cells, but also maintain the normal turnover of regenerative organs, such as blood, skin or intestinal tissues. As stem cells can be grown and transformed into specialized cells with characteristics consistent with cells of various tissues such as muscles or nerves through cell culture, their use in medical therapies has been proposed. In particular, embryonic cell lines, autologous embryonic stem cells generated through therapeutic cloning, and highly plastic adult stem cells from the umbilical cord blood or bone marrow are touted as promising candidates (*Tuch*, 2006).

The discovery of the pluripotent stem cells made the prospect of cell therapy and tissue regeneration a clinical reality that hold a great promise to repair, restore, replace affected organs (*Levicar et al.*, 2007).

Bone marrow derived stem cells represents a candidates for liver directed gene therapy and tool for the regenerative medicine (*Idilman et al.*, 2007).

Aim of the Essay

The aim of the essay is to review the subject of stem cell transplantation and to highlight its role in management of various liver diseases.

Stem Cell

Stem cell definition:

Stem cells are unspecialized cells that have two defining properties: the ability to differentiate into other cells and the ability to self regenerate (*Piscalgia et al.*, 2008).

Properties of stem cells

The classical definition of a stem cell requires that it possess two properties:

- Self-renewal the ability to go through numerous cycles of cell division while maintaining the undifferentiated state.
- Potency the capacity to differentiate into specialized cell types. In
 the strictest sense, this requires stem cells to be either totipotent or
 pluripotent to be able to give rise to any mature cell type, although
 multipotent or unipotent progenitor cells are sometimes referred to as
 stem cells (Takahashi and Yamanaka, 2006).

Potency specifies the differentiation potential (the potential to differentiate into different cell types) of the stem cell.

Totipotent stem cells are produced from the fusion of an egg and sperm cell. Cells produced by the first few divisions of the fertilized egg are also totipotent. These cells can differentiate into embryonic and extraembryonic cell types.

Pluripotent stem cells are the descendants of totipotent cells and can differentiate into cells derived from any of the three germ layers.

Multipotent stem cells can produce only cells of a closely related family of cells (e.g. hematopoietic stem cells differentiate into red blood cells, white blood cells, platelets, etc.).

Unipotent cells can produce only one cell type, but have the property of self-renewal which distinguishes them from non-stem cells (e.g. muscle stem cells) (Yu et al., 2007).




Fig. (1): Pluripotent, embryonic stem cells originate as inner mass cells within a blastocyst. The stem cells can become any tissue in the body, excluding a placenta. Only the morula's cells are totipotent, able to become all tissues and a placenta (*Jaenisch*, 2004).

History of stem cell

Hematopoietic stem-cell transplantation was originally conceived more than 50 years ago as a treatment for injury from irradiation and, later, for cancer, associated problems needed to be solved before the procedure could be used clinically. Bone marrow, the source of hematopoietic stem cells, is not a solid organ but is rather diffuse and not directly accessible.

Studies from the mid-20th century demonstrated that massive total-body irradiation causes fatal damage to the gastrointestinal and central nervous systems. Lower doses lead to delayed death from hemorrhage and infection. In animal models, the transplantation of genetically identical (syngeneic) marrow or the animal's own (autologous) stored marrow averted death. Grafts from histocompatible littermates also permitted survival. The transplantation of marrow that was not genetically identical (allogeneic) to that of the recipient resulted in an immunologic reaction by the donor lymphocytes against the recipient, causing inflammation of the target tissues, termed graft-versus-host disease (GVHD). Treatment with methotrexate suppressed GVHD. As an alternative to total-body irradiation, cyclophosphamide as a preparative regimen also permitted the engraftment of allogeneic marrow.

Thomas was a pioneer in applying the results from early studies in animals to the treatment of leukemia in people. In 1959, he and his colleagues reported that a patient with end-stage leukemia who was treated with total-body irradiation, followed by infusion of her identical twin's marrow, had a three-month remission (*Thomas et al.*, 1959).